The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Comparing salvage transplantion to CAR T-cell therapy for treating relapsed multiple myeloma
Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the findings of a retrospective analysis of a large European data set which aimed to compare the outcomes achieved with salvage transplantation strategies to those seen with CAR T-cell therapy in patients with relapsed multiple myeloma (MM). Although longer follow-up is necessary, superior outcomes were observed in those patients treated with CAR-T. However, the selection of the appropriate treatment option must be made on an individual basis, according to the eligibility criteria of the patient. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
